Sanderling Ventures

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Metavention, Inc., founded in 2012 and based in Dover, Delaware, specializes in developing innovative treatments aimed at permanently disrupting the overactive nerves that contribute to high blood pressure and various metabolic diseases. The company has created a renal denervation procedure that employs radio frequency energy to target and modulate overactive sympathetic nerves. This trans-catheter device not only addresses issues related to high blood pressure but also focuses on conditions such as Type 2 diabetes by employing standard interventional vascular techniques. By providing physicians with advanced tools for diagnosis and treatment, Metavention aims to enhance patient outcomes for those suffering from metabolic disorders linked to sympathetic nervous system activity.

PreciThera, Inc. is a biotechnology company based in Montreal, Canada, founded in 2016. It specializes in developing biological therapeutics for rare bone diseases, particularly targeting heterogeneous genetic disorders that manifest as bone dysfunction. By leveraging computational technology and a comprehensive understanding of disease pathology, PreciThera aims to create precision medicines that address both skeletal and extraskeletal symptoms associated with these conditions. Its targeted therapeutic strategies seek to enhance treatment options for patients, focusing on traditional protein replacement therapies to improve overall health outcomes.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

DalCor Pharmaceuticals, established in 2015, is a biopharmaceutical company specializing in precision medicine for cardiovascular diseases. Headquartered in Sarasota, Florida, with additional offices in Montreal, Zug, and Leatherhead, the company develops and commercializes targeted treatments based on patients' genetic profiles. DalCor's lead product, dalcetrapib, a cholesterol ester transfer protein inhibitor, is designed to reduce cardiovascular events in patients with a specific ADCY9 genetic profile, as demonstrated in a pharmacogenomics analysis of the dal-Outcomes study. The company holds a worldwide exclusive license for dalcetrapib and the ADCY9 genetic marker from Roche.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Liphorus Pharmaceuticals Inc. is a Montreal-based company established in 2014 that specializes in the development of pharmaceuticals aimed at treating hypercholesterolemia. The company focuses on creating small molecules and therapeutic antibodies that target PCSK9, a protein involved in cholesterol regulation. By developing these compounds, Liphorus Pharmaceuticals aims to provide innovative solutions for lowering LDL cholesterol levels effectively. The company has also entered into a research agreement with the IRCM to facilitate the creation and validation of its PCSK9-targeting compounds, further enhancing its capabilities in this therapeutic area.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

TheraVida, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic products specifically for urological disorders and central nervous system conditions. Established in 2005 and headquartered in California, TheraVida's primary emphasis is on improving treatments for overactive bladder (OAB) and urge urinary incontinence. Its flagship product, Tolenix, is a combination drug that integrates tolterodine, a muscarinic antagonist for OAB, with pilocarpine, a muscarinic agonist for dry mouth. This innovative drug platform aims to mitigate the common side effect of dry mouth associated with traditional anti-muscarinic therapies, thereby enhancing patient tolerability without compromising therapeutic efficacy. TheraVida's commitment to addressing the challenges of urological disorders positions it as a significant player in the biopharmaceutical landscape.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Infraredx, Inc. is a cardiovascular imaging medical device company focused on the diagnosis and treatment of coronary artery diseases. Founded in 1998 and headquartered in Burlington, Massachusetts, Infraredx specializes in near-infrared spectroscopy technology and its application in coronary imaging. The company develops and manufactures advanced imaging systems, including a dual-modality near-infrared spectroscopy intravascular ultrasound system, which allows for the identification of lipid core coronary plaques and provides structural information about plaque. Its product lineup also features the Makoto intravascular imaging system, the Dualpro catheter that combines intravascular ultrasound and near-infrared spectroscopy, and optical catheters for high-resolution imaging of plaque structures. Infraredx serves hospital sites across the United States and Europe and has been operating as a subsidiary of Goodman USA, Inc. since 2015.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Gemin X Pharmaceuticals is focused on the discovery, development, and commercialization of innovative cancer therapeutics aimed at improving patient outcomes. The company’s research centers on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070, also known as obatoclax. This small molecule is designed to selectively trigger programmed cell death, or apoptosis, and may also promote autophagy in cancer cells. Obatoclax has demonstrated encouraging results in preclinical and early clinical studies and is currently undergoing Phase 2 clinical trials, both as a standalone treatment and in combination therapies. In addition to obatoclax, Gemin X is developing GMX1777, an inhibitor of NAD+ synthesis, among other oncology products, providing patients with potential relief from various cancer conditions. The company holds patent protection for obatoclax until 2025.

Taligen Therapeutics is a biotechnology company dedicated to discovering and developing novel protein therapeutics aimed at modulating the alternative pathway of the complement system. This approach targets a critical amplification loop in the inflammatory process, which is significant for treating a variety of inflammatory conditions and diseases. The company's lead therapeutic candidates include monoclonal antibodies and recombinant fusion proteins designed to interact with key factors in the alternative pathway. By focusing on the regulation of the complement system, Taligen Therapeutics seeks to provide innovative solutions for inflammatory and immune diseases.

TheraVida, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic products specifically for urological disorders and central nervous system conditions. Established in 2005 and headquartered in California, TheraVida's primary emphasis is on improving treatments for overactive bladder (OAB) and urge urinary incontinence. Its flagship product, Tolenix, is a combination drug that integrates tolterodine, a muscarinic antagonist for OAB, with pilocarpine, a muscarinic agonist for dry mouth. This innovative drug platform aims to mitigate the common side effect of dry mouth associated with traditional anti-muscarinic therapies, thereby enhancing patient tolerability without compromising therapeutic efficacy. TheraVida's commitment to addressing the challenges of urological disorders positions it as a significant player in the biopharmaceutical landscape.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Gemin X Pharmaceuticals is focused on the discovery, development, and commercialization of innovative cancer therapeutics aimed at improving patient outcomes. The company’s research centers on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070, also known as obatoclax. This small molecule is designed to selectively trigger programmed cell death, or apoptosis, and may also promote autophagy in cancer cells. Obatoclax has demonstrated encouraging results in preclinical and early clinical studies and is currently undergoing Phase 2 clinical trials, both as a standalone treatment and in combination therapies. In addition to obatoclax, Gemin X is developing GMX1777, an inhibitor of NAD+ synthesis, among other oncology products, providing patients with potential relief from various cancer conditions. The company holds patent protection for obatoclax until 2025.

Neomend is a biomedical device company focused on developing and commercializing innovative surgical wound healing products. The company's primary technology is Pro/PEG, a bioadhesive polymer hydrogel designed to enhance the healing process. Neomend specializes in a combination wound sealant and adhesion barrier product that can be utilized during minimally invasive and laparoscopic procedures, improving patient outcomes and recovery times. Through its advanced technological solutions, Neomend aims to address critical needs in surgical wound management.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

NovoStent Corporation, a medical device company that has developed a novel "anchored" helical stent technology to provide a wide range of vascular therapies.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

Axikin Pharmaceuticals, Inc., a privately held biopharmaceutical company based in San Diego, California, specializes in developing and commercializing small molecule therapeutics for severe respiratory, inflammatory, and autoimmune diseases. Founded in 2008 as a spin-out from Actimis Pharmaceuticals, the company focuses on conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease, and rheumatoid arthritis. Axikin's platform includes novel therapeutics designed to address allergic respiratory disorders and inflammation associated with COPD.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Pacira BioSciences Inc. is a pharmaceutical company based in San Diego, California, specializing in non-opioid pain management and regenerative health solutions. Founded in 1989, it develops and manufactures injectable pharmaceutical products aimed at improving outcomes for healthcare practitioners and their patients. Pacira's portfolio includes three commercialized non-opioid treatments: EXPAREL, a long-acting local analgesic approved for postsurgical pain management; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis; and iovera, a handheld device that provides immediate, long-lasting, drug-free pain relief through controlled cold temperature delivery to targeted nerves.

ISTA Pharmaceuticals is a commercial-stage pharmaceutical company based in Irvine, California, focused on developing and marketing treatments for various eye diseases and conditions. Founded in 1992, the company specializes in remedies for ocular inflammation, glaucoma, dry eye, and allergies. Its marketed products include BROMDAY, an ophthalmic solution for postoperative inflammation and pain, BEPREVE for allergic conjunctivitis, ISTALOL for glaucoma, and VITRASE, used as a spreading agent in ocular treatments. ISTA is also engaged in developing several products, including over-the-counter artificial tears, PROLENSA for postoperative pain relief, and various nasal sprays for allergic rhinitis. The company sells its products to a broad range of customers, including drug wholesalers, retail pharmacies, hospitals, and managed healthcare providers. As of June 2012, ISTA Pharmaceuticals operates as a subsidiary of Bausch & Lomb Incorporated.

Altor BioScience Corporation is a biopharmaceutical company based in Miramar, Florida, specializing in the discovery, development, and commercialization of immunotherapeutic agents aimed at treating cancer, viral infections, and autoimmune diseases. Founded in 2002, the company focuses on the immunostimulatory properties of cytokines such as IL-15 and IL-2, which enhance the activation and proliferation of immune cells critical for combating malignancies and infections. Altor's product portfolio includes several candidates in various stages of development, such as ALT-801, a T-cell receptor-targeted therapy for cancer, and ALT-803, an IL-15 superagonist for solid tumors. Additionally, the company offers STAR Fusion and STAR Multimer Reagents for diagnosing and targeting cancer and viral infections, as well as tools for the detection of disease targets on cell surfaces. Altor BioScience aims to leverage its innovative technologies to advance treatment options for patients with challenging health conditions.

Gemin X Pharmaceuticals is focused on the discovery, development, and commercialization of innovative cancer therapeutics aimed at improving patient outcomes. The company’s research centers on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070, also known as obatoclax. This small molecule is designed to selectively trigger programmed cell death, or apoptosis, and may also promote autophagy in cancer cells. Obatoclax has demonstrated encouraging results in preclinical and early clinical studies and is currently undergoing Phase 2 clinical trials, both as a standalone treatment and in combination therapies. In addition to obatoclax, Gemin X is developing GMX1777, an inhibitor of NAD+ synthesis, among other oncology products, providing patients with potential relief from various cancer conditions. The company holds patent protection for obatoclax until 2025.

Actimis Pharmaceuticals, Inc. is a start-up biopharmaceutical company dedicated to developing small molecule therapeutics aimed at treating respiratory, inflammatory, and autoimmune disorders. Established as a spin-off from Bayer Healthcare AG's research portfolio, the company was founded by Dr. Kevin Bacon, who previously served as Vice President and Global Head of Respiratory Diseases research at Bayer Yakuhin Ltd. Actimis focuses on creating effective treatments for conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease, and rheumatoid arthritis, thereby providing physicians with innovative options to manage these challenging diseases. The company has attracted venture financing from notable investors, positioning itself to advance its therapeutic pipeline.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company is focused on creating nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., it underwent a name change to CoMentis in February 2007 after merging with Zapaq, Inc., which strengthened its position in the neurovascular disease sector. CoMentis is headquartered in South San Francisco, California.

Asteres Inc. is a San Diego-based company specializing in pharmacy automation technology, founded in 2003. The company develops and installs kiosks and lockers for the secure and efficient pickup of prescriptions and healthcare products in various settings, including retail stores, hospitals, corporate workplaces, and military bases. Its flagship product, ScriptCenter, functions similarly to an ATM, allowing consumers to collect and pay for their prescriptions at their convenience, even when pharmacies are closed or during busy hours, thereby minimizing wait times and enhancing customer experience. Asteres also offers the ScriptCenter MX kiosk for automated pickup and payment of pharmacist-filled prescriptions and a modular ScriptCenter Locker System to accommodate different prescription pickup volumes. Additionally, Asteres provides integration services for IT, pharmacy management, and payment systems, along with marketing, branding, maintenance, and support services, emphasizing customer value and service in the healthcare automation sector.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Infraredx, Inc. is a cardiovascular imaging medical device company focused on the diagnosis and treatment of coronary artery diseases. Founded in 1998 and headquartered in Burlington, Massachusetts, Infraredx specializes in near-infrared spectroscopy technology and its application in coronary imaging. The company develops and manufactures advanced imaging systems, including a dual-modality near-infrared spectroscopy intravascular ultrasound system, which allows for the identification of lipid core coronary plaques and provides structural information about plaque. Its product lineup also features the Makoto intravascular imaging system, the Dualpro catheter that combines intravascular ultrasound and near-infrared spectroscopy, and optical catheters for high-resolution imaging of plaque structures. Infraredx serves hospital sites across the United States and Europe and has been operating as a subsidiary of Goodman USA, Inc. since 2015.

Taligen Therapeutics is a biotechnology company dedicated to discovering and developing novel protein therapeutics aimed at modulating the alternative pathway of the complement system. This approach targets a critical amplification loop in the inflammatory process, which is significant for treating a variety of inflammatory conditions and diseases. The company's lead therapeutic candidates include monoclonal antibodies and recombinant fusion proteins designed to interact with key factors in the alternative pathway. By focusing on the regulation of the complement system, Taligen Therapeutics seeks to provide innovative solutions for inflammatory and immune diseases.

Asteres Inc. is a San Diego-based company specializing in pharmacy automation technology, founded in 2003. The company develops and installs kiosks and lockers for the secure and efficient pickup of prescriptions and healthcare products in various settings, including retail stores, hospitals, corporate workplaces, and military bases. Its flagship product, ScriptCenter, functions similarly to an ATM, allowing consumers to collect and pay for their prescriptions at their convenience, even when pharmacies are closed or during busy hours, thereby minimizing wait times and enhancing customer experience. Asteres also offers the ScriptCenter MX kiosk for automated pickup and payment of pharmacist-filled prescriptions and a modular ScriptCenter Locker System to accommodate different prescription pickup volumes. Additionally, Asteres provides integration services for IT, pharmacy management, and payment systems, along with marketing, branding, maintenance, and support services, emphasizing customer value and service in the healthcare automation sector.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Neomend is a biomedical device company focused on developing and commercializing innovative surgical wound healing products. The company's primary technology is Pro/PEG, a bioadhesive polymer hydrogel designed to enhance the healing process. Neomend specializes in a combination wound sealant and adhesion barrier product that can be utilized during minimally invasive and laparoscopic procedures, improving patient outcomes and recovery times. Through its advanced technological solutions, Neomend aims to address critical needs in surgical wound management.

Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Cylene Pharmaceuticals, Inc. is a biotech pharmaceutical company based in San Diego, California, focused on the discovery and development of small molecule drugs targeting cancer cells. The company specializes in nucleolus targeting agents, which are designed to provide targeted therapeutic solutions for carcinoid and neuroendocrine tumors as well as pediatric brain tumors. Additionally, Cylene develops serine/threonine protein kinase inhibitors and pre-clinical stage oral drug candidates. Established in 1997 as Cyternex, Inc., the company rebranded to Cylene Pharmaceuticals in October 2003. Its innovative approach aims to activate p53 through non-genotoxic pathways, offering improved treatment options for various cancer indications.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company is focused on creating nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., it underwent a name change to CoMentis in February 2007 after merging with Zapaq, Inc., which strengthened its position in the neurovascular disease sector. CoMentis is headquartered in South San Francisco, California.

Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Xytis is a biopharmaceutical company focusing on the discovery and development of innovative CNS drug candidates. The company is privately held and was created in Jan 2006 by the merger of Xytis Pharmaceuticals Ltd. (UK) and Remergent, Inc. (USA). The company received funding from Sanderling Ventures, Atlas Venture, CDC Entreprises Innovation, and Ventech. Xytis Inc. is assembling a pipeline of innovative compounds with validated mechanisms of action, addressing major unmet clinical needs in CNS fields such as Schizophrenia, Traumatic Brain Injury, Depression, Anxiety, or Insomnia. The company has two clinical stage compounds in development and operates from the USA, UK and Switzerland.

Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

Infraredx, Inc. is a cardiovascular imaging medical device company focused on the diagnosis and treatment of coronary artery diseases. Founded in 1998 and headquartered in Burlington, Massachusetts, Infraredx specializes in near-infrared spectroscopy technology and its application in coronary imaging. The company develops and manufactures advanced imaging systems, including a dual-modality near-infrared spectroscopy intravascular ultrasound system, which allows for the identification of lipid core coronary plaques and provides structural information about plaque. Its product lineup also features the Makoto intravascular imaging system, the Dualpro catheter that combines intravascular ultrasound and near-infrared spectroscopy, and optical catheters for high-resolution imaging of plaque structures. Infraredx serves hospital sites across the United States and Europe and has been operating as a subsidiary of Goodman USA, Inc. since 2015.

Actimis Pharmaceuticals, Inc. is a start-up biopharmaceutical company dedicated to developing small molecule therapeutics aimed at treating respiratory, inflammatory, and autoimmune disorders. Established as a spin-off from Bayer Healthcare AG's research portfolio, the company was founded by Dr. Kevin Bacon, who previously served as Vice President and Global Head of Respiratory Diseases research at Bayer Yakuhin Ltd. Actimis focuses on creating effective treatments for conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease, and rheumatoid arthritis, thereby providing physicians with innovative options to manage these challenging diseases. The company has attracted venture financing from notable investors, positioning itself to advance its therapeutic pipeline.

Asteres Inc. is a San Diego-based company specializing in pharmacy automation technology, founded in 2003. The company develops and installs kiosks and lockers for the secure and efficient pickup of prescriptions and healthcare products in various settings, including retail stores, hospitals, corporate workplaces, and military bases. Its flagship product, ScriptCenter, functions similarly to an ATM, allowing consumers to collect and pay for their prescriptions at their convenience, even when pharmacies are closed or during busy hours, thereby minimizing wait times and enhancing customer experience. Asteres also offers the ScriptCenter MX kiosk for automated pickup and payment of pharmacist-filled prescriptions and a modular ScriptCenter Locker System to accommodate different prescription pickup volumes. Additionally, Asteres provides integration services for IT, pharmacy management, and payment systems, along with marketing, branding, maintenance, and support services, emphasizing customer value and service in the healthcare automation sector.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Artielle ImmunoTherapeutics, Inc. is a biopharmaceutical company based in Tigard, Oregon, established in 2004. The company specializes in developing biologic drugs that target inflammatory and degenerative diseases, with a particular focus on neuro-inflammatory conditions. Artielle's platform includes recombinant T-cell receptor ligands (RTLs), which are designed to treat T-cell mediated inflammatory diseases. Key areas of development include therapies for multiple sclerosis, celiac disease, type 1 diabetes, rheumatoid arthritis, uveitis, stroke, and optic neuritis. By targeting the CD74 receptor on monocytes and inhibiting the action of macrophage migration inhibitory factor, Artielle ImmunoTherapeutics aims to provide innovative solutions for patients suffering from these challenging conditions.

Zapaq, Inc. is a privately held biopharmaceutical company focused on discovering an developing therapeutics that target aspartic proteases, a group of enzymes central to a variety of human diseases, including Alzheimer's. The company is headquartered in Waltham, MA and has research and development operations in Oklahoma City, OK.

CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.

Kadmus Pharmaceuticals, Inc., a biopharmaceutical company, commercially exploits endocannabinoid pathways to develop therapeutics. Endocannabinoids are naturally occurring signaling molecules, whose functions include regulating mood, pain, and metabolism. It offers a portfolio of compounds with activity against a range of disorders targeting CNS conditions, metabolic disorders, neuropathic pain, and obesity. The company develops products for various conditions through the inhibition of endocannabinoid degradation and activation of endocannabinoid related pathways and peripheral cannabinoid receptors. It operates in the United States, Canada, and Europe. Kadmus Pharmaceuticals, Inc. was founded in 1998 and is based in Irvine, California.

Asteres Inc. is a San Diego-based company specializing in pharmacy automation technology, founded in 2003. The company develops and installs kiosks and lockers for the secure and efficient pickup of prescriptions and healthcare products in various settings, including retail stores, hospitals, corporate workplaces, and military bases. Its flagship product, ScriptCenter, functions similarly to an ATM, allowing consumers to collect and pay for their prescriptions at their convenience, even when pharmacies are closed or during busy hours, thereby minimizing wait times and enhancing customer experience. Asteres also offers the ScriptCenter MX kiosk for automated pickup and payment of pharmacist-filled prescriptions and a modular ScriptCenter Locker System to accommodate different prescription pickup volumes. Additionally, Asteres provides integration services for IT, pharmacy management, and payment systems, along with marketing, branding, maintenance, and support services, emphasizing customer value and service in the healthcare automation sector.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Infraredx, Inc. is a cardiovascular imaging medical device company focused on the diagnosis and treatment of coronary artery diseases. Founded in 1998 and headquartered in Burlington, Massachusetts, Infraredx specializes in near-infrared spectroscopy technology and its application in coronary imaging. The company develops and manufactures advanced imaging systems, including a dual-modality near-infrared spectroscopy intravascular ultrasound system, which allows for the identification of lipid core coronary plaques and provides structural information about plaque. Its product lineup also features the Makoto intravascular imaging system, the Dualpro catheter that combines intravascular ultrasound and near-infrared spectroscopy, and optical catheters for high-resolution imaging of plaque structures. Infraredx serves hospital sites across the United States and Europe and has been operating as a subsidiary of Goodman USA, Inc. since 2015.

CyThera, Inc., headquartered in San Diego, CA, is a biotechnology company focused on developing cell replacement therapies for the treatment of human degenerative diseases. The company's proprietary technology platform enables the expansion and proliferation of functional human cells that can be used to treat human degenerative disease.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.

Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

Cylene Pharmaceuticals, Inc. is a biotech pharmaceutical company based in San Diego, California, focused on the discovery and development of small molecule drugs targeting cancer cells. The company specializes in nucleolus targeting agents, which are designed to provide targeted therapeutic solutions for carcinoid and neuroendocrine tumors as well as pediatric brain tumors. Additionally, Cylene develops serine/threonine protein kinase inhibitors and pre-clinical stage oral drug candidates. Established in 1997 as Cyternex, Inc., the company rebranded to Cylene Pharmaceuticals in October 2003. Its innovative approach aims to activate p53 through non-genotoxic pathways, offering improved treatment options for various cancer indications.

Aderis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cardio-renal diseases. The company focuses on creating novel small-molecule, receptor-specific therapeutics, including adenosine agonists and antagonists, which are designed to diagnose and treat cardiovascular conditions. Additionally, Aderis is developing leukotriene synthesis inhibitors aimed at managing chronic renal disease. The company also has strategic license agreements that involve late-stage products for treating Parkinson's disease and diagnosing coronary artery disease. By targeting specific proteins to either enhance or inhibit their activity, Aderis aims to improve patient outcomes and quality of life while minimizing side effects associated with treatments.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.

BioSpace Inc., headquartered in Englewood, Colorado with a satellite office in San Francisco, operates BioSpace.com, an online platform dedicated to serving the life science community. It offers an extensive job board, daily news feeds, and community features that facilitate connections among recruiters, job seekers, and professionals in biotechnology, pharmaceuticals, medical devices, diagnostics, clinical research, academia, and biomedical industries across North America. BioSpace also hosts career events for recruitment professionals. Formerly a subsidiary of DHI Group Inc., the company aims to accelerate communication and discovery within the life science sector by providing essential insights, opportunities, and tools for both innovative organizations and talented professionals worldwide.

CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.

Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.